At Prescient, science is at the core of everything we do.
We are a product and portfolio strategy partner that specializes in turning the science of molecules into optimal patient outcomes and client value.
Prescient’s Environmental, Social & Governance (ESG) Program
To best serve our clients in their efforts to improve the well-being of patients around the world, Prescient’s actions enhance the well-being of its internal and external stakeholders, the communities in which it operates, and the planet as a whole.
A little about us...
Founded in 2007, Prescient is a global firm with a footprint in ten cities across three continents. Our team of nearly 500 experts partners with 27 of the top 30 biopharmaceutical companies, the fastest-growing mid-caps and cutting-edge emerging biotechs, including some of the biggest and most innovative brands.
More than 80% of our employees hold advanced life sciences or relevant degrees, and our teams deliver an impressive depth of therapeutic, clinical and commercial expertise.
Meet Our Leadership
Jamie is our CEO and a career consultant, having spent more than 20 years growing and managing pharmaceutical-focused insight and advisory firms. In 2007, he became the managing director of a global competitive strategy firm and led the company’s transition from an industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient in 2010, led a management buyout in 2014 and the investment by Baird Capital in 2017 and Bridgepoint Development Capital (BDC) in 2021. Jamie remains actively involved with our clients, mainly focusing on brand planning, mature brand strategies and strategy workshops.
Rakesh is the President of our Intelligence & Insight business. After earning a degree in veterinary medicine, he completed his MS in immunology and his PhD in immunology/oncology at Imperial College, School of Medicine, London. He was then recruited by oncology biotechnology firm Antisoma, which specialized in the development of antibodies-based therapeutics for oncology. After working in oncology drug development for more than a decade, Rakesh joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.
Debasish is the President of our Advisory business. A physician by training, Debasish is a seasoned strategy advisor to biopharmaceutical leadership. After a brief stint early in his career at P&G, Debasish spent 10 years at Bain & Company, where he was a leader in the healthcare practice. Debasish has extensive international experience across the US, EU and APAC markets advising biopharmaceutical leaders on value creation through corporate, business unit, disease area and product-focused strategies.
Steve is President of our Commercial business. Prior to this, he was Managing Director and one of the founding partners of Strategic North. He spent the first part of his career in brand and innovation consultancy, working with a wide range of international brand-led businesses. He brings a forward-looking and customer-centric brand mindset to everything we do.
With over 30 years’ experience, Steve is quick to see the big picture, never one to accept the status quo and a passionate believer in the power of the team – all qualities he brings to bear on everything he does, whether it’s your brand or ours.
Swati is the President of our sizable India-based business operations. She has an MSc in biotechnology and pharmacology and an MBA from the University of Sheffield. After joining us in London in 2008, Swati moved to India in 2010 to set up the New Delhi office, which she has built into a critical part of our business. She has also been responsible for setting up the InflexionRx® Software Development team and the Prescient Data & Analytics team in India. Swati has extensive experience in consulting biopharma companies on new and mature brand planning strategies. She has directed engagements across multiple therapeutic areas and geographies, with a focus on the APAC region.
Alex Panayi serves as Prescient’s CFO. After studying at the London School of Economics and qualifying as a chartered accountant at KPMG, Alex spent over 20 years working for large multinational organizations, including Thorn EMI, BAA and Lend Lease. He most recently spent 14 years at global sustainability consultancy ERM, where he successfully supported the business through three private equity transactions. At Prescient, Alex will oversee the company’s finance functions.
Gerald is our Chief Strategy Officer, based out of our London office. He is a molecular biologist by training and completed his PhD in anti-microbial drug discovery under the highly regarded Glaxo Scholarship program. After several years of working across drug discovery and development, both in Europe and in North America, Gerald transitioned to the world of management consulting. Since then, he has spent the last 20 years working exclusively with the healthcare and life sciences sectors, including leading practices at McKinsey & Company and KPMG, serving clients across the value chain encompassing R&D strategy, clinical development strategy, portfolio strategy, medical affairs strategy and value and access strategy. At Prescient, Gerald will lead the charge in shaping and executing our ambitious growth strategy to deliver on our vision and mission.
Paul oversees our business activities in North America. Since completing his PhD in chemistry at Stony Brook University, he has spent more than 20 years providing guidance and support to the healthcare industry. He has held leadership roles at various consulting firms, such as Deloitte and Quintiles, that engage with biopharmaceutical and medical technology companies in nearly all functional areas, including sales, marketing, medical affairs, business development and supply chain. Paul’s focus at Prescient is helping our clients achieve and sustain peak commercialization targets across a wide range of therapy areas.
Victoria is a Vice President and our Chief Talent Officer. She has a bachelor’s degree (with honors) in economics from Nottingham Trent University, as well as several accounting and human resources certifications. Victoria spent more than 20 years in senior leadership positions at KPMG across the EU and Asia, where she developed extensive experience and a proven ability to implement change in complex and cross-cultural environments. At Prescient, her role involves working with senior stakeholders to effectively prioritize and execute the activities needed to achieve defined strategic objectives.
Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgery before joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.
Alan is a founder Partner of Bridgepoint Development Capital. He sits on the BDC Board, Operating Committee and is a member of its Investment Advisory Committee. He joined Bridgepoint in 1996. Alan is currently a board member of portfolio companies Matrix and HKA. He has led a broad range of transactions including public to private and serial international buy and build investments. Previous transactions include Quotient Clinical, Phlexglobal, LOC Group, BigHand, The Energy Solutions Group, Pulsant and Safestore PLC. Prior to joining Bridgepoint he worked for Deloitte (formerly Arthur Andersen) in their corporate finance team. Alan has a degree in Finance from Birmingham University and is a Chartered Accountant.
Stephen is a Partner within Bridgepoint Development Capital and leads BDC’s Healthcare and Life Science practice. He joined the team in 2007. He has worked on a number of transactions, spanning a range of sectors, including investments in HKA, The Dining Club Group, Quotient Clinical, Phlexglobal, MVF, Inspired Thinking Group, Solhaga, Memnon Networks and Shimtech Industries. Prior to Bridgepoint Stephen worked at Deloitte within its M&A division where he advised on mid-market buyouts, principally in the Healthcare sector. Stephen qualified as a Chartered Accountant and holds the Chartered Financial Analyst designation. He also holds a postgraduate degree in Accounting and Finance from the University of Natal, South Africa.
Debbie is a Senior Vice President in our Commercial Advisory business. She has a track record of more than 25 years working in a variety of global and national marketing roles for AstraZeneca followed by the leap to the consultancy world, where she built a successful brand building and insights consultancy called Strategic North with fellow co-founders David, Steve and Michael. Debbie is passionate about working collaboratively with clients to build successful brands starting from early in the life cycle through to launch and beyond, bringing substantial knowledge and experience in creating actionable strategies that achieve tangible results.
Kevin is a Vice President in our Advisory business and leads our Boston office. He earned his BSc in neuroscience and economics from Brown University and has since worked in life sciences and biopharmaceutical strategy consulting, spending the better part of a decade at ClearView Healthcare Partners before joining Prescient. Kevin has led multiple engagements across a range of therapeutic areas and geographies. He is experienced in target product profile development and evaluation, therapeutic area and indication prioritization, competitive strategy, opportunity assessment, due diligence, life cycle management and clinical development strategy. At Prescient, Kevin ensures client satisfaction through high-quality, tailored and targeted recommendations.
Harminder is a Vice President and has been delivering high-impact projects to our clients since 2010. He earned his MS in chemistry from Virginia Commonwealth University and his BPharm from Panjab University. He is also a registered pharmacist. Before joining Prescient, he worked in pharmaceutical product manufacturing, regulatory and corporate departments. At Prescient, Harminder focuses on analyzing competitors and market scenarios for biosimilar, generic and novel products. He also works at building client relationships and motivating teams to better serve our clients’ needs.
Erica is a Vice President and the Head of Advisory for the US at Prescient. She has over 15 years of experience in healthcare consulting and biotechnology, including eight years at the Boston Consulting Group, where she served as the North America topic leader for launch in biopharma. Prior to joining Prescient, Erica was a Vice President at Zymergen, a synthetic biology company, where she led strategy and managed technical delivery teams. She specializes in biopharma strategy and has experience across many therapeutic areas. Erica earned her PhD from Princeton University in cognitive psychology and her MBA from MIT Sloan. At Prescient, Erica focuses on uncovering and understanding the drivers of decision making and translating them into actionable recommendations for clients.
Courtney, our Associate Vice President of Operations, joined Prescient in 2012. After earning a master’s degree in Spanish translation, she pursued a job opportunity in Bogotá, Colombia, where she translated medical, legal and technical texts and designed an assessment program to monitor the quality of her fellow translators’ work. Courtney is responsible for various operational aspects of our business, including quality control, compliance and US resourcing.
Katy is a Associate Vice President in our Advisory business. Since earning her master’s degree in bioscience from Keck Graduate Institute, she has acquired several years of experience in life science management consulting, advising clients on brand, commercialization and corporate portfolio strategy engagements. She has focused on late-stage, pre-launch assets across various disease areas, including oncology, hematology, dermatology and rare diseases. At Prescient, Katy’s focus is on driving the growth of the Advisory team by ensuring engagements are of high quality, expanding Prescient Advisory’s presence and supporting team professional development.
David is a Senior Vice President at Prescient and prior to that was a founding partner and Client Relationship Director at Strategic North. He has over 25 years’ experience in the pharma industry across market research and strategic brand building. He has been part of a leadership team that has built three successful pharma consultancy practices. He brings deep expertise in understanding customer beliefs and behaviors and translating these insights into brand strategy. He combines this with great people skills to ensure clients are inspired about the future possibilities for their brand. He is passionate about engaging with a diverse range of stakeholders in healthcare and positively impacting patients’ lives.
Ben is a Vice President and supports both our East and West Coast clients in the US. He holds a BSc in biomedical sciences and an MSc in biomedical engineering, and he gained eight years of experience in biotechnology prior to joining Prescient in 2010. Ben has held progressively more senior roles at Prescient, which has given him a deep understanding of what is needed to build and motivate teams that deliver results with a high degree of client satisfaction. Ben has also been closely involved in managing projects across multiple therapeutic areas, including oncology, immunology and biosimilars.
Olga is an Associate Vice President in our Advisory business. She is a medical doctor, with a master’s degree in medicine of the pharmaceutical industry from the Autonomous University of Barcelona, and has completed the IESE Management Development Program and ESADE Leadership and Marketing Master. She has more than 30 years’ experience working in the pharmaceutical industry in both large multinational and medium-sized companies such as Sanofi, Lundbeck and Ferrer, as well as at the consultancy firm KPMG, where she held various leadership positions. She has deep experience at international level across the whole pharmaceutical value chain in multiple therapy areas. At Prescient, Olga is responsible for championing the development of the Barcelona-based Advisory team, contributing to growing our European Advisory business and supporting our clients to address their strategic and operational challenges.
Mark is the Senior Vice President of our North American business. After completing a PhD in biochemistry at The Ohio State University, he spent more than 10 years running GSK’s competitive strategy function and 10 years as a key member of Covance’s executive strategy team. Mark engaged with Prescient throughout his tenure with GSK and Covance before joining us in 2013. He is responsible for establishing, solidifying and expanding client relationships by engaging with industry executives and bringing clarity to our solutions.
Aviral is a Vice President at Prescient. He completed his MBBS and MS degrees at Jawaharlal Nehru Medical College, India, and his MBA at IESE Business School, Spain. Aviral has developed a strategic understanding of both the clinical and commercial sides of the life sciences industry from working as a physician for eight years and holding strategic consultancy roles at GSK and Grail Research. Since joining Prescient in 2010, Aviral has examined all aspects of product life cycle for companies developing biologics, biosimilars and generics, OTC medicines, vaccines and medical devices within CVMD, respiratory disease, gastroenterology, immunology, dermatology, neurology and ophthalmology.
Andrew joined our team in 2012 after holding finance director positions in marketing services companies, such as Publicis and Gyro. He is a qualified chartered accountant and holds an honors degree in accountancy from Dundee University. He manages Prescient’s finances and is the company secretary. He was heavily involved in setting up the shared resources service center in the UK and arranging Prescient’s de-merger/MBO in 2014 and taking Prescient through two rounds of private equity investments in 2017 and 2021.
Tarun is spearheading the development of our InflexionRx® platform. He obtained his master’s degree in computer applications from M.B.M Engineering College, and he has more than 18 years of experience in product management, enterprise application design and development and entrepreneurship. He has worked with small- to medium-sized technology start-ups and is an expert in product ideation, conceptualization, development from proof of concept to final products, and market releases. At Prescient, Tarun’s role involves leading and delivering a software platform that creates value for our clients and drives efficiencies among our project teams.
Jeanne is a Vice President at Prescient. Prior to joining Prescient, she spent more than 25 years providing strategic insight and planning support to the biopharmaceutical industry. Jeanne has held leadership roles at various companies, including EMD Serono and Genzyme. She brings a depth of biopharmaceutical experience in brand and strategic planning, indication prioritization, competitive intelligence, workshop design and facilitation, and the integration of multiple external perspectives to inform decision making. At Prescient, Jeanne leverages her expertise in rare diseases, multiple sclerosis, immunology, inflammatory diseases and fertility to grow and develop client relationships and lead client engagements.
Elisavet is a Vice Prescient and joined Prescient in 2008. She holds a PhD in molecular immunology and an MSc in medical genetics from Brunel University London, as well as a BSc in biology from the Royal Holloway University of London. As a consultant in the pharmaceutical industry, Elisavet has gained extensive experience in various aspects of drug development and commercialization, strategic marketing and life cycle management, providing critical analyses and recommendations to brand teams supporting new and existing products in oncology, malignant and non-malignant hematology, vaccines, rare diseases and other areas. Elisavet uses her expertise in evidence gathering to identify key unmet needs, gaps in strategy, opportunities for differentiation and potential threats.
Luke is a Vice President and Head of our European Advisory business based out of our London office. After studying medicine and working as a doctor in the UK for several years, Luke spent the rest of this career in consulting roles at various firms including McKinsey & Company and Strategy&. He has led and delivered projects across most of the pharmaceutical value chain, as well as multiple therapy areas and geographies. Luke brings deep experience in value and access strategy, portfolio strategy, clinical development strategy, medical affairs strategy, commercial due diligence and life cycle management. At Prescient, Luke is responsible for growing our European advisory business and helping our clients address their biggest market access hurdles to maximize their brand’s value.
Anthony is one of the longest-serving members of our team, having joined in 2002. He earned his PhD in pharmacology before becoming a postdoctoral researcher at the University of Southampton. From there, he joined the world of healthcare market research, working for the likes of MMR International, IMS Health and NOP World (now GfK). He has consulted across the therapeutic spectrum and throughout the product life cycle but particularly enjoys developing clinical strategies within oncology, infectious diseases and cardio-metabolic diseases.
Michael, a Senior Vice President at Prescient, was founder and Business Unit Director of Strategic North. Michael draws on a wealth of knowledge and experience from building a successful global consultancy, as the Head of Client Services for a healthcare communications agency and being a Global Commercial Lead in corporate, all underpinned by his MBA and degree in biochemistry. He embodies the intellect and creative energy that shapes great brand strategy combined with the commercial astuteness to realize the full value of a brand, portfolio or franchise.
Nishika has over 5 years of healthcare consulting experience spanning diverse functions such as market research, strategy consulting and competitive intelligence in various therapeutic areas including immunology, rare diseases and infectious diseases. She holds a Master’s degree in Microbial Technology. Prior to joining Prescient, she worked as a project manager at SmartAnalyst India Private Limited, where her role was to lead end-to-end consulting projects for Fortune 100 pharmaceutical clients. She devised business development proposals to win new consulting projects for the organization.
Apart from healthcare consulting, Nishika has also tracked and analyzed events impacting the commercial potential of a biosimilar (blockbuster drug) in the immunology space across developed markets. She was also involved in creating comprehensive research books and newsletters identifying forward-looking strategies in various autoimmune indications.
Alyssa is an Associate Director in our Commercial Strategy business. She has a specific interest and expertise in fusing key stakeholder insights into a robust brand strategy. Alyssa has over seven years of brand planning, market research and account management experience in both agency and consultancy settings. She enjoys tackling complex challenges in healthcare and strives to always bring a positive energy to her work. Alyssa is responsible for client management of key accounts and leading teams to build out strategies with clarity and innovation.
Simon, a marketing strategy specialist, is a Senior Director at Prescient. His career history includes seven years in FMCG, 12 years ‘client side’ in pharma in a range of global and US leadership positions, and over eight years in strategy consulting. Simon joined Strategic North in 2016 and has led a wide range of projects across the product life cycle. He specializes in brand planning, positioning, competitor strategy, value proposition development and brand activation.
Helena brings over 20 years’ experience in global pharmaceutical market research and, since joining Strategic North in 2017, brand strategy. Over this time, she has worked in a broad range of therapy areas including oncology, rare diseases, devices and diagnostics, and ophthalmology, and supported brands across the life cycle.
Her extensive experience has brought a deep understanding of the demands and challenges clients may face, and the importance of engaging and action-oriented deliverables for maximum project benefit. Equally, Helena’s inquisitive thinking ensures that all our client’s commercial challenges are explored.
Tanya is a Director at Prescient. She previously served as a corporate communications and investor relations executive for small- and mid-cap pharmaceutical companies, and has more than 15 years of experience as an academic neuroscientist. Since joining Prescient in 2016, Tanya has applied a combination of academic rigor and real-world insight to address her clients’ needs. She has provided dozens of new and mature brand product teams with top-quality business intelligence acquired through research and conference attendance. Tanya is passionate about bridging communication divides between thought leaders and industry experts.
Jyotsana is a Director responsible for our secondary Data & Analytics hematological portfolio (including multiple myeloma, DLBCL and AML). She has been responsible for delivering disease- and mechanism-based competitive landscapes and datasets supporting our product, commercial and therapy area strategy analyses. Jyotsana has an MSc in clinical research and worked with IMS Health (now IQVIA) and SmartAnalyst India Pvt Ltd as part of her prior engagements. She has 14 years of experience in oncology research and analytics and has been instrumental in setting up teams and processes for syndicated offerings and customized client engagements. Jyotsana has expertise in clinical trial analysis and insight generation and has been extensively involved in conceptualization, structuring and process layouts for multiple cancer reports and databases, including both solid and hematological malignancies.
Sarah is our Head of People and Culture and joined Strategic North when it was founded in 2010. She has over 25 years’ experience in HR, operations and finance, working with some of the biggest PR and marketing agencies in the UK and Australia. Sarah’s energy, passion and enthusiasm put her at the heart of the Strategic North culture. She is a highly skilled people person, responsible for all elements of our People & Culture strategy, ensuring we recruit, develop and retain the right people to deliver against our overall business strategy. She makes sure that the unique culture we have created is protected and sustained through living our values.
Peter is one of our Directors and works across our Advisory and Intelligence & Insight businesses. After earning a degree in life sciences, he gained a first-class master’s degree in business at Edinburgh Napier University and a postgraduate qualification in health economics at Aberdeen University. Peter has held scientific, development and commercial leadership roles within the CRO, pharmaceutical and biopharmaceutical industries with Charles River Laboratories, Kyowa Kirin and Ablynx NV, respectively. He has been the Global Launch Director for two orphan drug monoclonal antibody launches, both for the treatment of rare diseases. At Prescient, Peter is responsible for leading successful Intelligence & Insight and Advisory engagements.
Shweta joined the Prescient team in 2015 and is now a Director in our Intelligence & Insight business. She has a master’s degree in biotechnology and bioinformatics from La Trobe University in Australia. She began her professional career more than 12 years ago in life sciences consulting. Since then, she has been part of several organizations where she supported successful medicine launches that positively impact patients’ lives. Besides consulting, Shweta has experience as a scientific writer and has authored several publications for some of the top brands in pharma. At Prescient, Shweta is responsible for managing key accounts, building and coaching the Prescient team and creating an unmatched, high-quality experience for our clients
Paula joined our team in 2015 and is a now a Director in our Intelligence & Insight business. She holds an MSc in medical biology from the University of Oviedo, Spain. She began her academic research career at the University of Roehampton London, investigating the mechanism of metastasis in multiple tumors. At Prescient, Paula coordinates a wide range of engagements with our clients within the oncology space, with a particular focus on drug development strategy and competitive pipeline analysis. She uses her deep knowledge and expertise across treatment paradigms and market dynamics in oncology to advise our clients’ strategies in this area.
Anamika heads the Talent and Performance Management Function of our India operation. She is an alumna of IIM Raipur and has an MBA in human resource management. She has more than 10 years of experience in the field of human resources and has worked in diverse industries. At Prescient, Anamika is responsible for talent acquisition and talent development, and she continues to play a pivotal role in the growth and development of our India team.
Easha is a Senior Director in our Intelligence & Insight business. She has a degree in life sciences and an MBA in marketing and strategy from the Indian School of Business. She has more than 12 years of industry experience and a proven track record of turning compelling market insights into differentiated strategies and solutions. She has worked across the business value chain from R&D, new product launch and commercialization to the life cycle management of brands in various therapy areas. She has held strategic and marketing roles in various biopharmaceutical companies and led the launches of two blockbuster products in oncology. At Prescient, Easha directs global competitive intelligence programs for leading biopharmaceutical companies.
Gordon is a Senior Director in our Intelligence & Insight business. He earned his MBA in market and strategy from Carnegie Mellon University and his BA in biochemistry from the University of Pennsylvania. He has over 15 years of dedicated oncology experience in market research and competitive intelligence. Before joining Prescient, Gordon led teams working on projects across the development timeline at Kantar Health, AlphaImpactRx (now part of IQVIA) and Psyma. At Prescient, Gordon is responsible for driving our business growth by expanding our presence, ensuring high-quality engagements and supporting team development.
Nadia joined the Prescient team as the US Financial Controller and HR Director. After earning her accounting degree, she developed financial expertise through her work with high-end retail and luxury brands headquartered in New York City. While working in retail, Nadia was responsible for the financial reporting and oversight of nationally recognized brands with a presence across the country. The technical expertise and business acumen she has acquired over the past 15 years have proven to be invaluable assets to our organization.
Lee is a consulting director with over 20 years’ experience that spans multiple global roles across pharma and consumer healthcare multinationals. Having worked extensively at the intersection of commercial strategy, emerging science and customer insight, he is well-placed to lead cross-functional client teams through a wide range of strategic challenges. Lee also has significant brand strategy experience in the fields of immunology and infectious diseases, working across the development life cycle from early asset development to mature inline brands.
John is a Senior Director with 20 years of experience in partnering with healthcare clients across insight and strategy workstreams at a local, regional and global level. John has a passion for developing new research methodologies and approaches to get to the heart of what makes customers tick and to unravel why they do what they do. He also has a flair for developing impactful deliverables that galvanize teams and for facilitating action-orientated workshops to drive alignment around decision making.
John has been nominated for and won numerous awards for his work and has spoken at BHBIA and EphMRA conferences.
Jatin is a Senior Director in our Intelligence & Insight business and has been with Prescient since 2014. He holds a master’s degree in biotechnology from the University of Manchester and has worked within the pharmaceutical analysis divisions of major organizations, such as Bloomberg. At Prescient, Jatin has directed several global projects while working across domains, including immunology, oncology, hematology, neurology, nephrology, endocrinology, respiratory disease and biosimilars. He applies his broad experience and strategic mindset to a variety of engagement types ranging from intelligence-driven consultative projects to strategy development support.
Gareth joined Strategic North in August 2014 and has over 12 years’ experience of pharmaceutical brand strategy and market research. Gareth has a particular passion for ensuring customer understanding is at the heart of strategic decision making and driving alignment and clarity across client teams that enables consistent implementation. In the office, Gareth is often the instigator of team lunches, and outside of work, is kept busy by his two young boys, Teddy and Archie, and trying to pass on his love for football, golf, rugby and squash.
Bharat is a Director in our Intelligence & Insight business. He has been with Prescient since 2014 and specializes in oncology, immunology, neuroscience and rare diseases. He holds an MS in biotechnology and entrepreneurship from New York University. He has directed several engagements focused on the US, EU and global markets across various areas and topics of interest, including regulatory strategies, clinical development, new product commercialization, mature brand planning, and others. Bharat is responsible for managing key client accounts, driving business growth and leading internal development activities.
Claudio is a Director in our Advisory business. Since earning his MBA from the IESE Business School and a double BSc degree in chemical and mechanical engineering from the IQS School of Engineering (Universitat Ramon Llull), Claudio has spent his career in consulting roles at various firms including IQVIA and two of the ‘Big Four’ professional services firms. He has led and delivered strategy consulting projects across multiple therapy areas, especially in the fields of commercial strategy, commercial excellence/SFE, portfolio strategy, life cycle management, corporate strategy, M&A and market access strategy. At Prescient, Claudio is responsible for building our Spanish Advisory team and supporting the growth of our European Advisory business.
Rachna is a Director at Prescient. She has a degree in pharmacy and an MBA in pharmaceutical marketing. She has over 10 years of experience in strategic consulting and competitive intelligence spanning various therapeutic areas including oncology, vaccines and biosimilars. At Prescient, Rachna directs global competitive intelligence programs for leading biopharmaceutical companies and is responsible for driving business growth by ensuring high-quality engagements and supporting team development.
Priya is a Director in our Intelligence & Insight business. She earned her PhD in molecular biology from the New Jersey Medical School and her MBA in pharmaceutical management and marketing from Rutgers Business School. Priya has over 15 years of healthcare experience, having served as a subject matter expert and trusted advisor for her clients. She has co-authored several peer-reviewed scientific articles and industry-relevant white papers. At Prescient, Priya is responsible for driving growth within our Intelligence & Insight business, managing key business accounts and providing strategic leadership in coaching teams to deliver successful engagements.
Jen is our Business Partner. After completing a natural sciences and management studies degree at Cambridge University, Jen started her career as a strategy and operations management consultant with Deloitte. Having worked with global and European clients across industries delivering a diverse range of finance advisory and transformation projects, she moved to GSK, where she held various transformation and partnering roles across finance services, corporate and more recently in R&D. Jen is a qualified management accountant (ACMA GCMA) and is PRINCE 2 and Lean Six Sigma qualified. She is an experienced finance business partner and transformation professional with industry and consulting experience. At Prescient, Jen acts as a business partner to leadership across the organization and is supporting the business to develop more impactful and insightful decisions supported by data as well as supporting business improvement initiatives.
Emma is a Senior Director within the InflexionRx® team. She has over 10 years of experience, having worked in the UK NHS and private pharmaceutical companies, delivering technology and organizational transformation, including process design, establishment of centers of excellence, management reporting and analytics across a range of companies, countries and industries. At Prescient, her role drives our InflexionRx™ strategy, developing frameworks and ways of working to ensure a consistent, quality structure for our clients. She works with both client and internal teams to roll out the platform and embed it within our business and client interactions.
Chris is a Consulting Director at Strategic North, with nine years of experience working with global brand and insights teams to understand market dynamics, opportunities and implications for brand and portfolio development.
Chris partners with global clients to support pipeline, pre-launch and in-line brand decision-making, portfolio and disease area strategy. He recently partnered with a global commercial capabilities and excellence team to develop a business-wide approach to early asset vision and strategy development. He combines close collaboration and technical understanding with genuine curiosity to learn about the ‘today and tomorrow’ of healthcare, and to deeply understand evolving therapy areas.
Rob is a Director within the InflexionRx® team, and he holds an MSc in biomedical engineering from Columbia University and a BASc in biomedical engineering from Bucknell University. For over 10 years, Rob has led diverse projects in strategy and intelligence for several biopharmaceutical companies in various therapeutic areas, and his analyses have been featured in numerous well-known publications. At Prescient, Rob manages the InflexionRx™ decision support platform used to organize intelligence, craft strategies and develop deep insights. He heads change management, client adoption and platform implementation, and he further guides software development and expansion of the platform’s footprint with new clients.
Cameron is a Senior Director in our Intelligence & Insight business. He earned his PhD in biophysical chemistry from the University of Glasgow, his MSc in chemistry from the University of Strathclyde and his MBA from Strathclyde Business School. He has over 15 years of experience in the pharmaceutical and biotechnology industries, having worked for both established firms and start-ups in R&D, manufacturing, BD, licensing and IP management. At Prescient, Cameron is responsible for leading high-quality engagements with new and existing clients and applying his knowledge and experience to answer their strategic business questions.
Christina is our Senior Director of Global Marketing and heads up all marketing and communications functions. After earning a master’s degree in pharmaceutical business, she pursued careers in both the non-profit and commercial sectors. Her experience includes leading marketing strategy for global oncology teams, as well as regionally for the Americas and in emerging markets with Kantar’s Health Division. Christina is responsible for elevating the positioning and messaging of the Prescient brand through the development of strategic marketing programs and thought leadership initiatives.
Amol Padgaonkar is a Director in our Intelligence & Insight business with over seven years of experience strategically supporting clients across the life sciences industry. In particular, Amol is deeply familiar with the oncology, hematology and inflammatory disease therapeutic areas; with expertise across various forms of engagements, Amol’s primary strategic focus includes early asset, asset life cycle and portfolio/therapeutic area planning. He enjoys serving as a critical thought partner for clients, leveraging his disease area content expertise and strategic insights to drive actionable and innovative solutions. Prior to joining Prescient, Amol received his PhD in molecular biology and cancer genetics from the Temple University School of Medicine in Philadelphia and completed his postdoctoral research at Mount Sinai School of Medicine in New York, where his thesis focused on the discovery and development of novel oncogenic kinase targets and inhibitors in triple-negative breast cancer.
Chris joined us having spent just under a decade at a global consumer healthcare company, working at the intersection of commercial strategy, brand innovation and portfolio management. Chris relishes the opportunity to build collaborative partnerships. He always endeavors to uncover the human truth behind the data that will resonate with the brand, customer and ultimately the patient. Chris has significant oncology, respiratory and rare blood disorder brand strategy experience across the development life cycle from early asset development to mature, inline brands.
Kallal is one of the longest-serving members of our India-based team. He has master’s and doctoral degrees in biotechnology, as well as a master’s degree in business administration. After holding various academic research posts in oncology, Kallal became a Lead Scientist at Connexios Life Sciences, where the focus of his group was to design in vitro and ex vivo assays reflecting human pathologies in type 2 diabetes mellitus and to test the efficacy of in-house drugs. Since joining Prescient in 2010, Kallal has managed new product and mature product brand planning projects in the areas of neurology, oncology, immunology and diabetes in both the regulated and semi-regulated markets.
Emmanuel is a Senior Director in our Intelligence & Insight business. He holds an MD from the University of Cincinnati College of Medicine and an MSc in immunology from the Medical University of South Carolina. Emmanuel co-founded a consulting firm to help integrate technology and healthcare, originally centered on the implementation and optimization of electronic health record systems. After several years growing the business, he entered the pharmaceutical sector as a clinical trial manager. He has experience conducting clinical and preclinical research in liquid tumors and molecular biology. At Prescient, Emmanuel leverages his clinical and research experience to support clients as they navigate the complexities of bringing new therapies to patients in need.
Ben is a Consulting Director in our Commercial Strategy business with a passion to build effective brand and disease area strategies. He is an expert in designing and executing strategy workshops, delivering cross-functional alignment and energizing client teams. Ben is responsible for leading successful partnerships with teams across a range of therapy areas such as oncology, immunology and neuroscience.
Josh is a Consulting Director, specializing in integrating brand strategy with customer insight. His comprehensive expertise and strategic thinking spans many disease areas (including cardiometabolic conditions, neurology and hematology), across both blockbuster brands and rare disease assets. Motivated by building lasting relationships with teams, he brings a personal approach and energy to understanding the unique brand dynamics and challenges in order to collaboratively uncover the optimal opportunities that lie between brand objectives and true customer need.
Josh is responsible for overseeing key client accounts and leading teams in delivering fresh and meaningful recommendations to complex questions, informing actionable commercial strategy.
Anna leads the Finance and Business Operations function. She has strong skills in financial planning and reporting along with good business acumen, supporting both the executive board and management team in decision making.
Prior to joining Strategic North, Anna trained and qualified for her CIMA accountancy qualification at N Brown Group PLC. Over the last 20+ years, she has held various roles in finance, including roles at Marks & Spencer, TDG and a number of SMEs.
Ranjini is responsible for enabling organizational change and transformation at Prescient, working globally to help our leaders and teams deliver on their growth strategies and transformational goals. She has spent over 20 years working for large multinational organizations, including PwC, Barclays, KPMG, Vodafone, EDF Energy and renewable energy company RES, and in that time she has led several large, complex projects through ambiguous and rapidly changing environments and helped clients realize value through their transformation agendas. She has worked in numerous countries across a variety of sectors, enabling transformations stemming from both organic and inorganic growth. She has a Bachelor of Engineering degree from Visvesvaraya National Institute of Technology, India, and a Master’s degree in human resources, accredited by the CIPD in the UK.
Nila joined Strategic North in July 2021 and is leading the quant-enabled strategy arm. In her 20 plus years as an insights and brand strategy professional, Nila has worked across a range of geographies and cultures, helping businesses join the dots between insight and strategy by understanding their key stakeholders and then establishing a unique way of connecting with them. Skilled in the application of quant techniques from classic to advanced analytics, Nila has in recent years focused on leveraging technology across the research spectrum to deliver meaningful learnings that drive material improvements in strategy and performance.
Ashima, a physician by training, is a Senior Director at Prescient. Her career has included positions with medical institutions, insurance companies and consulting firms. Ashima joined Prescient in 2014, where she works extensively in biosimilars, hematology and rare diseases. Ashima leads client engagements related to strategic BD&L decisions, competitive intelligence, product label design, commercialization planning, life cycle management and financial modeling.
Gaurav is a Director responsible for our newest secondary Data & Analytics immunology portfolio, (including atopic dermatitis and psoriasis), and is also leading teams across diverse therapeutic areas on trackers and ad hoc requests. Prior to this, Gaurav was responsible for our secondary Data & Analytics oncology portfolio (including breast, head and neck and prostate cancers). He has been instrumental in guiding the teams in product, clinical and commercial strategy analyses. Gaurav holds a PhD in nanomedicine from the University of Strathclyde, Glasgow, and an MS in pharmaceutics from the National Institute of Pharmaceutical Education and Research (NIPER). In his previous engagements, Gaurav served as a Feasibility Specialist with Syneos Health (Pfizer business unit), providing insights and recommendations in hematological malignancies trials, and with WNS Pvt Ltd (GSK unit) in the competitive intelligence franchise. Gaurav has 12+ years of experience in oncology, immunology, neurology and rare disease consulting and insights generation, along with experience in scientific analytics and KOL management.
Shweta is a Director responsible for our secondary Data & Analytics solid tumors portfolio (including lung cancer, melanoma, breast cancer and prostate cancer). She has been responsible for delivering disease area-based competitive landscapes and datasets supporting our product, commercial and therapy area strategy analyses. Shweta has an MBA in pharmaceutical management from NIPER (Mohali) and has worked with IMS Health (now IQVIA) and SmartAnalyst India Pvt Ltd as part of her prior engagements. She has 14 years of experience in oncology research and analytics, consulting and database tool management. She has been instrumental in setting up teams, processes and ensuring data quality in various customized client engagements. Shweta has an expertise in clinical trial analysis and insight generation and has been extensively involved in conceptualization, structuring and process layouts for multiple cancer reports and databases, including both solid and hematological malignancies.
Reena is a Director in our Intelligence & Insight business. With more than a decade of clinical and pharmaceutical industry experience, Reena’s expertise spans consulting, medical affairs, clinical development and medical writing across different therapy areas. She practiced as a physician before transitioning to work with various pharmaceutical companies. In addition to her medical degree, she holds a postgraduate certificate in Quality and Accreditation of Health Care Organizations. At Prescient, Reena leads multi-dimensional engagements for global pharmaceutical organizations to support their business intelligence strategies across various stages of the product life cycle.
Mladen is a Senior Director in our Intelligence & Insight business. He received his PhD in microbiology from the University of Minnesota and completed his postdoctoral research at Columbia University. Before joining Prescient, Mladen oversaw analyst teams and market research portfolios at Decision Resources Group across various therapeutic areas. Previously, he worked at Merck & Co. and MedImmune/AstraZeneca, where he led projects focused on the discovery of novel anti-infectives for the treatment and prevention of serious bacterial infections. At Prescient, he is responsible for leading engagements across different therapeutic areas.
Nick, a Senior Director, has a PhD in pharmacology from the University of London, and he has conducted postdoctoral research at London’s Royal Postgraduate Medical School. He began his career in the pharmaceutical industry as a senior scientist to lead the pharmacology effort on discovery research projects in airway diseases at Rhône-Poulenc (now Sanofi) and in asthma and type 2 diabetes at SmithKline Beecham (now GSK). He then spent nearly 19 years as a senior equity analyst at Mirabaud Securities and Jefferies, with responsibility for the pharmaceutical and biotechnology industries. At Prescient, Nick supports our clients as a subject matter expert in oncology and hematology.
Christian is a Director and head of our Advisory team based in Munich. After studying physics and completing his PhD in molecular biology at ETH Zurich, he worked as a research associate at Harvard Medical School for three years; Christian then spent his career in consulting roles at BCG, Syneos Health and Trinity Life Sciences. Most recently, his work has focused on supporting biopharma companies prepare for the commercial launches of novel therapies in Europe. He is skilled in working with cross-functional teams and in leveraging his experience in commercial, medical affairs and market access. Christian has extensive experience across therapeutic areas, with a focus on rare diseases and novel technology platforms, including cell and gene therapies. At Prescient, Christian is responsible for building our German Advisory team to support the growth of our European business.
Diane Whelan is Prescient’s first Head of Learning and is responsible for building out Prescient Academy, a program focused on developing those critical skills and experiences that enable us to offer world-class services to our clients, as well as providing development pathways for our talented team members. Diane brings a wealth of global learning experience that she has gained across several sectors from her work in both corporate roles and as a consultant in leadership and management development. She has worked within professional services for the last 10 years, building consulting, leadership, professional and business development capabilities; furthermore, Diane holds an MSc in management learning from Lancaster University, is a fellow of the Learning and Performance Institute (LPI) and is a chartered member of the Chartered Institute of Personnel and Development (CIPD).
Dan is a Consulting Director at Prescient with over 10 years of experience in global, regional and UK market research in addition to brand strategy. He has worked in a broad range of therapeutic areas, including oncology, rare diseases, immunology, vaccines and metabolic diseases, amongst others, supporting both pre-launch and in-line brands. Dan’s collaborative working style with clients, as well as his desire to uncover behavioral drivers across HCPs, patients and payers, enables him to focus on the small details that enhance brand strategy. He is motivated by building longstanding partnerships and facilitating action-orientated workshops, using insights to navigate through complexity and providing a springboard to action. In July 2022, Dan became a Board member of the British Healthcare Business Intelligence Association (BHBIA).
Yasemin is a Director in our Intelligence & Insight business, leading key global oncology accounts and driving business growth. She has more than 10 years of pharmaceutical industry experience supporting products and portfolios from clinical drug development to commercialization and delivering evidence-based clinical, regulatory and commercial strategy analyses for marketed and pipeline products. Yasemin has extensive experience in oncology and worked across a wide range of other therapeutic areas, including rare diseases and immunology.
Maksim is a Director in our Intelligence & Insight business. He earned his PSM in biotechnology from Temple University, where he gained an advanced understanding of industries across the life sciences sector. At Prescient, Maksim leverages his deep clinical and commercial knowledge to help his global clients answer complex business questions across a wide range of disease areas, such as hematology, rheumatology, dermatology and respiratory. He also takes on an active role in training and mentoring junior analysts, thus helping his team members achieve their personal career goals.
Ishaan joined our team in January 2021 as a Consultant. After receiving his undergraduate and master’s degrees from UCL in biology and molecular medicine, respectively, he started his career in the NHS in a variety of administrative and research positions at University College Hospital, London. He then transitioned to healthcare market research spending several years at Hall & Partners where he worked across different therapy areas. At Prescient, Ishaan actively seeks opportunities to use his research and storytelling capabilities to deliver valuable insights to our clients.
Dr. Flavia Marialucia Fioretti
Flavia based in our London office. She holds a PhD and MRes in oncology and drug development from Imperial College London and an MSc in molecular biology from University Federico II of Naples, Italy. Prior to joining Prescient, she worked as a clinical project manager in early-phase clinical trials, supporting pharmaceutical companies in designing trial protocols using her expert regulatory and GCP knowledge. She has published five papers in international peer-reviewed journals, been an invited speaker at international conferences and won multiple scholarships and awards. At Prescient, Flavia leads projects involving pharmaceutical competitive strategy, regulatory landscape for drug approval and market access.
Jessica joined our team in October 2020 as our People and Culture Manager. She has gained 7 years’ experience as an HR professional after completing her degree in social psychology from Loughborough University and CIPD level 7 advanced diploma in human resource management. At Prescient, Jessica is responsible for shaping our people strategy and supporting our team to achieve their goals.
Mega is based in our New Delhi office. She completed her Master’s degree in biotechnology at Amity University. Prior to joining Prescient, she spent a decade working with pharmaceutical and medical technology companies based in India in various functional areas, including sales, marketing and business development. At Prescient, Mega has been involved in projects across various domains, including immunology, oncology, respiratory diseases and biosimilars.
Carly is based in our Jersey City office. She completed her MSc in biomedical science at the Icahn School of Medicine at Mount Sinai, where her research focused on the treatment of pulmonary hypertension through the development of a novel therapeutic and investigation into the role of miRNAs in lung pathology. Previously, she completed her BSc in neuroscience at the University of Miami. At Prescient, Carly has worked on a variety of medical affairs, market access and commercial strategy projects with and large biotech and pharmaceutical companies, specializing in various therapy areas including oncology, ophthalmology and respiratory diseases.
Dr. Lauren Kershberg
Lauren is based in our Boston office. Prior to joining Prescient, she completed her PhD in neurobiology at Harvard University and BA in neuroscience at Pomona College. Her background is in synaptic neurobiology; as part of her thesis work, she studied the proteins that are involved in the precise regulation of dopamine release. At Prescient, Lauren drives clinical data analyses, primary and secondary research and specializes in medical affairs strategic planning.
Sonia is based in our Barcelona office. She holds a PhD in biochemistry and microbiology from Imperial College London and an MSc in infectious diseases from University College London. Prior to joining Prescient, she worked as an associate at Imperial Consulting Group where she devised the market entry strategy for a point-of-care diagnostic test for infectious diseases. She has published four papers in peer-reviewed journals, been an invited speaker at international conferences and won multiple scholarships and awards. At Prescient, Sonia leads projects involving competitive landscape and commercial strategy analysis, including launch strategies across multiple therapeutic areas.
Dr. Melanie Rodrigues
Melanie is based in our San Mateo office. She has completed her PhD in cell and molecular biology at the University of Pittsburgh in collaboration with the Massachusetts Institute of Technology. Following her PhD, she received the Wound Healing Foundation’s 3M Fellowship and became an Instructor at Stanford University School of Medicine. She then worked at Orca Bio, developing bone marrow transplants for patients with certain high-risk blood cancers. She has 14 years of experience working in the cell therapy space and has contributed to over 40 publications in regenerative medicine. At Prescient, Melanie oversees competitive intelligence projects in cell therapy and oncology.
Ishita Das Sarkar
Ishita is based in our New Delhi office. She has completed her diploma and degree in aircraft maintenance engineering from Singhania University and her Master’s degree in aviation management from ICFAI University. Prior to joining Prescient, she supported technology offerings within a pharma startup company. At Prescient, she works diligently on optimizing our InflexionRx® platform for internal and external users and supports consistent and creative UX/UI experiences.
Supriya is a Senior Associate with an MD from Brown University. Prior to entering medicine, she completed her BA in public health from Johns Hopkins University and her master’s in environmental health sciences, with concentrations in risk science, bioethics and economics, from the Johns Hopkins Bloomberg School of Public Health. She offers expertise across multiple therapeutic areas, integrating diverse perspectives, conducting primary and secondary research, and in tracking clinical and regulatory developments for products across all stages of the life cycle. Additionally Supriya is a certified yoga and mindfulness teacher, with a strong history of volunteerism and social justice advocacy, including serving as a volunteer EMT/firefighter and as an advocate for victims of domestic violence, the homeless and the LGBTQ+ community. Supriya aims to support corporate mentorship and sponsorship initiatives, as well as foster a culture of inclusivity, diversity and compassion across employee experiences.
Collaborate with a Proven and Trusted Partner
Our average partnerships with product teams last more than five years. Prescient adapts to you as your needs change – from molecule to product, product to brand, and brand to the realization of your commercial goals.
We believe that the respect and trust of our clients must be continuously earned. We strive to achieve this by collectively challenging and supporting each other to be the best we can and by individually taking ownership, being accountable and making a difference.
Our vision is to be the biopharma strategy partner most respected for its people, expertise and impact.
Our mission is to help biopharmaceutical companies develop, launch and market medicines that expand treatment options, optimize patient outcomes and deliver high levels of return.
We believe that the respect and trust of our clients must be continuously earned. We strive to achieve this by collectively challenging and supporting each other to be the best we can and by individually taking ownership, being accountable and making a difference.